(AMBEA) Ambea - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0009663826

AMBEA: Care, Nursing, Homes, Schools, Rehabilitation, Services

Ambea AB (publ) stands as a cornerstone in the Nordic care sector, delivering elderly care, disability care, and psychosocial support primarily across Sweden, Norway, and Denmark. Established in 1993 and headquartered in Solna, Sweden, the company has cultivated a diversified portfolio that addresses a spectrum of care needs, making it a resilient investment opportunity.

Ambeas operational structure is segmented into five distinct brands, each tailored to specific care niches. Nytida specializes in social care services and schools for children and young people with neuropsychiatric disorders, addressing a critical and specialized need. Vardaga and Altiden focus on elderly care, offering nursing homes and home care services, capitalizing on the growing demographic of aging populations. Stendi provides a broad range of services, including personal assistance and residential care, ensuring versatility in meeting diverse client needs. Klara complements these services with staffing solutions and ambulatory care teams, crucial for maintaining high service quality and efficiency.

Beyond direct care, Ambeas Lära brand underscores its commitment to excellence through skills development and coaching programs. These programs ensure that staff are well-trained, enhancing service quality and ensuring compliance with regulatory standards, which is vital for sustained operational excellence and trust.

From a financial perspective, Ambea presents a compelling profile. With a market capitalization of approximately 7,806.84M SEK, the company demonstrates moderate valuation with a P/E ratio of 13.47. The P/B ratio of 1.64 indicates a market valuation exceeding book value, likely reflecting intangible assets such as brand reputation and operational expertise. The P/S ratio of 0.56 suggests a favorable value proposition, appealing to investors seeking growth in the healthcare sector driven by demographic trends.

For investors and fund managers, Ambeas diversified service offerings and strategic focus on quality and compliance position it as a stable investment in the growing healthcare landscape. Its emphasis

Additional Sources for AMBEA Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AMBEA Stock Overview

Market Cap in USD 884m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Facilities
IPO / Inception

AMBEA Stock Ratings

Growth Rating 59.9
Fundamental 76.0
Dividend Rating 53.1
Rel. Strength 80.5
Analysts -
Fair Price Momentum 122.13 SEK
Fair Price DCF 510.58 SEK

AMBEA Dividends

Dividend Yield 12m 1.49%
Yield on Cost 5y 3.57%
Annual Growth 5y 6.87%
Payout Consistency 75.0%

AMBEA Growth Ratios

Growth Correlation 3m 61.3%
Growth Correlation 12m 95.8%
Growth Correlation 5y 23.2%
CAGR 5y 21.23%
CAGR/Max DD 5y 0.37
Sharpe Ratio 12m 1.42
Alpha 73.28
Beta 0.818
Volatility 35.55%
Current Volume 74.7k
Average Volume 20d 222.9k
What is the price of AMBEA stocks?
As of April 19, 2025, the stock is trading at SEK 110.40 with a total of 74,697 shares traded.
Over the past week, the price has changed by +6.15%, over one month by -0.72%, over three months by +17.38% and over the past year by +79.55%.
Is Ambea a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Ambea (ST:AMBEA) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 75.95 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMBEA as of April 2025 is 122.13. This means that AMBEA is currently undervalued and has a potential upside of +10.63% (Margin of Safety).
Is AMBEA a buy, sell or hold?
Ambea has no consensus analysts rating.
What are the forecast for AMBEA stock price target?
According to ValueRays Forecast Model, AMBEA Ambea will be worth about 133.2 in April 2026. The stock is currently trading at 110.40. This means that the stock has a potential upside of +20.63%.
Issuer Forecast Upside
Wallstreet Target Price 129.3 17.1%
Analysts Target Price - -
ValueRay Target Price 133.2 20.6%